Novo Nordisk A/S (NYSE:NVO) Shares Sold by LVW Advisors LLC

LVW Advisors LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,153 shares of the company’s stock after selling 1,091 shares during the quarter. LVW Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,217,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the third quarter valued at $48,000. Finally, M&R Capital Management Inc. boosted its holdings in Novo Nordisk A/S by 260.5% in the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after acquiring an additional 297 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NVO. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Trading Down 5.2 %

Shares of NVO opened at $78.74 on Monday. The stock’s 50-day moving average is $97.76 and its two-hundred day moving average is $117.05. The stock has a market cap of $353.33 billion, a PE ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.